Opinion|Videos|June 13, 2024
Intravesical Novel Therapy for HR BCG-Unresponsive NMIBC
Author(s)Gary Steinberg, MD, FACS
Gary D. Steinberg, MD, analyzes data from the BOND-003 study presented at AUA 2024, which investigated the use of intravesical cretostimogene grenadenorepvec for treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, and discusses the mechanism of action of this novel oncolytic viral therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Interim data from BOND-003 were just recently presented during the AUA 2024: (A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ).
- What is the mechanism of action of cretostimogene?
Advertisement
Related to this article
enGene expects to initiate a BLA submission by the end of 2026.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Virtuoso Surgical expects to initiate a focused US launch at leading urology centers in 2027.
The combination of nogapendekin alfa inbakicept plus BCG demonstrated a statistically significant improvement in efficacy vs BCG alone.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5